Literature DB >> 23571761

Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET.

Asae Nozawa1, Ali Hosseini Rivandi, Santosh Kesari, Carl K Hoh.   

Abstract

PURPOSE: To retrospectively assess the utility of (18)F fluorodeoxyglucose (FDG) positron emission tomography (PET) images of standardized uptake values corrected for blood glucose (SUV(gluc)), and to compare this to various quantitative methods to identify the presence or absence of high grade malignancy.
METHODS: A retrospective review in 42 patients, found 81 central nervous system (CNS) lesions. Fifty one were malignant and 30 were benign or post treatment changes based on pathology (n = 32) and on clinical outcome (n = 49). Dynamic FDG PET scans were processed to generate parametric images of SUV(gluc), SUV, glucose metabolic rate (GMR), and lesion to cerebellum ratios (SUV(Rc)), and contralateral white matter ratios (SUV(Rw)). The SUV(gluc) was calculated from SUV(max) * BG/[100 mg/dl], where SUV(max) is the maximum SUV and BG is the blood glucose level (mg/dL).
RESULTS: Using a malignant threshold for SUV(gluc) of 4.5 and GMR of 13.0 μmole/min/100 g, the accuracies were similar for the SUV(gluc) (80%) and GMR (81%) and were higher than the conventional SUV(max) (73%). The area under the receiver operating characteristic (ROC) curve for the SUV(gluc) (0.8661) was better than that for the SUV(max) (0.7955) (p < 0.02) and was similar to those of the GMR (0.8694), SUV(Rc) (0.8278), and SUV(Rw) (0.8559).
CONCLUSION: These results suggest that the SUV(gluc) may assist in the interpretation of FDG PET brain images in patients with CNS lesions. The SUV(gluc) method avoids the complexity of kinetic modeling and the definition of a reference region.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571761     DOI: 10.1007/s00259-013-2396-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.

Authors:  Ching-Yee Oliver Wong; Joseph Thie; Kelly J Parling-Lynch; Dana Zakalik; Jeffrey H Margolis; Marianne Gaskill; Jack Hill; Feng Qing; Darlene Fink-Bennett; Conrad Nagle
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

2.  Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy.

Authors:  Georg M N Behrens; Anne-Rose Boerner; Klaus Weber; Joerg van den Hoff; Johann Ockenga; Georg Brabant; Reinhold E Schmidt
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Can the standardized uptake value characterize primary brain tumors on FDG-PET?

Authors:  R Hustinx; R J Smith; F Benard; A Bhatnagar; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-11

4.  Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy.

Authors:  Y Menda; D L Bushnell; M T Madsen; K McLaughlin; D Kahn; K H Kernstine
Journal:  Nucl Med Commun       Date:  2001-10       Impact factor: 1.690

5.  Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET.

Authors:  Sang Mi Lee; Tae-Sung Kim; Jeong Won Lee; Seok-Ki Kim; Sang-Jae Park; Sung-Sik Han
Journal:  Clin Nucl Med       Date:  2011-05       Impact factor: 7.794

Review 6.  Pseudoprogression: relevance with respect to treatment of high-grade gliomas.

Authors:  James Fink; Donald Born; Marc C Chamberlain
Journal:  Curr Treat Options Oncol       Date:  2011-09

Review 7.  Pseudoprogression and pseudoresponse in the treatment of gliomas.

Authors:  Dieta Brandsma; Martin J van den Bent
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

8.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

9.  A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma.

Authors:  T K Narayanan; Sinan Said; Jogeshwar Mukherjee; Brad Christian; Martin Satter; Kelly Dunigan; Bing Shi; Martin Jacobs; Theodore Bernstein; Madakasira Padma; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2002-03       Impact factor: 3.488

10.  Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.

Authors:  Naruhide Kimura; Yuka Yamamoto; Reiko Kameyama; Tetsuhiro Hatakeyama; Nobuyuki Kawai; Yoshihiro Nishiyama
Journal:  Nucl Med Commun       Date:  2009-08       Impact factor: 1.690

View more
  6 in total

1.  Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules.

Authors:  Amin Haghighat Jahromi; Farshad Moradi; Carl K Hoh
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

2.  Quantification of tumour (18) F-FDG uptake: Normalise to blood glucose or scale to liver uptake?

Authors:  Georgia Keramida; Sabina Dizdarevic; Janice Bush; A Michael Peters
Journal:  Eur Radiol       Date:  2015-04-22       Impact factor: 5.315

3.  Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Predict Health Outcomes in Patients with Sarcoma.

Authors:  Brent Foster; Robert D Boutin; Leon Lenchik; David Gedeon; Yu Liu; Vinay Nittur; Ramsey D Badawi; Chin-Shang Li; Robert J Canter; Abhijit J Chaudhari
Journal:  J Nat Sci       Date:  2018

4.  Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.

Authors:  Asae Nozawa; Ali Hosseini Rivandi; Masayuki Kanematsu; Hiroaki Hoshi; David Piccioni; Santosh Kesari; Carl K Hoh
Journal:  Nucl Med Commun       Date:  2015-06       Impact factor: 1.690

Review 5.  Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.

Authors:  K Mariam Slot; Dagmar Verbaan; Dennis R Buis; Linda J Schoonmade; Bart N M Berckel; W Peter Vandertop
Journal:  J Neuroimaging       Date:  2020-11-02       Impact factor: 2.486

Review 6.  Dynamic FDG-PET demonstration of functional brain abnormalities.

Authors:  Mark Quigg; Bijoy Kundu
Journal:  Ann Clin Transl Neurol       Date:  2022-09-07       Impact factor: 5.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.